Aurobindo Pharma Share Price in Focus; Completes Transfer of Domestic Branded Generics Business to Auropharm

Aurobindo Pharma Limited has completed the transfer of its domestic branded generic pharmaceutical formulations products business to Auropharm Limited, marking the completion of an internal business restructuring announced earlier this year. 

The transfer became effective from 1 July 2026, following the fulfilment of all terms under the Business Transfer Agreement (BTA) between the two entities.  

Business Shift to Wholly Owned Subsidiary 

The transferred business will now be operated by Auropharm Limited, a wholly owned subsidiary of Aurobindo Pharma that was previously known as Auro Pharma Limited. 

According to the company, the transfer covers its domestic branded generic pharmaceutical formulations products business, which has now officially moved to the subsidiary from the effective date.  

Transfer Process Completed 

Aurobindo Pharma had first announced the transaction on 6 April 2026, when it entered into the Business Transfer Agreement with Auropharm Limited. 

The transaction has now been completed as a going concern and executed on a slump sale basis, with the company confirming that all conditions under the agreement have been fulfilled. As a result, the transferred business is now being undertaken by Auropharm Limited from 1 July 2026.  

About Aurobindo Pharma 

Aurobindo Pharma Limited is a pharmaceutical manufacturer with operations across generic formulations, active pharmaceutical ingredients (APIs), injectables, biosimilars and specialty products.  

The company supplies medicines to domestic and international markets and has a presence across multiple therapeutic segments. 

Read More: Adani Ports Share Price in Focus as Q1 FY27 Cargo Volume Rises 15% to 138.1 MMT! 

Aurobindo Pharma Share Price Performance  

As of 02 July 2026, at 12:32 PM, Aurobindo Pharma Limited share price was trading at ₹1,557 per share, reflecting a surge of 0.28% from the previous trading session. 

Conclusion 

With the completion of the Business Transfer Agreement, Aurobindo Pharma has transferred its domestic branded generic pharmaceutical formulations products business to Auropharm Limited, its wholly owned subsidiary, with effect from 1 July 2026. 

Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi.  

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.